← board
EXOZ
distress 8/10 · high distress / dilution risk$5.120%today-69% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
0.2 yrs
Shares 1y
+1%
Price & events
-55.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-17.7%
1W
-33.5%
1M
-50.4%
3M
-56.8%
6M
-46.1%
1Y
—
2Y
—
5Y
-40.8%
All
Overview
- Market Cap
- $43.39M
- Volume
- 1.33K
- 52 Week Range
- $5.12 – $16.50
- Total Shares
- 8.48M
- Float Shares
- 6.32M
- Short %
- 0.32%
- % Held by Insiders
- 64.53%
- % Held by Institutions
- 0.68%
- RVOL
- 0.10x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- July 1, 2026trial initiationsecondarycannabinoid analogs · NIH-funded SBIR Phase IIB grant work begins to develop cannabinoid analogs for drug discovery.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-09Price to sales forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
- 2026-07-08eXoZymes Inc. (EXOZ) Slips 2.96% – Testing Key Support Near $7.17 - Smart Beta Flow - dars.gov.et
- 2026-07-01eXoZymes (NASDAQ: EXOZ) raises $639K in unit sale with resettable warrants - Stock Titan
- 2026-07-01eXoZymes Raises $0.64 Million Via Unit Offering; Adds MDB Placement Pact and Warrant Coverage - TradingView
- 2026-06-26eXoZymes awarded $2.03M NIH SBIR grant to develop cannabinoid analogs - TradingView
- 2026-06-24exoZymes receives $2M NIH grant for cannabinoid research - Investing.com
- 2026-06-24NIH backs eXoZymes' cannabinoid drug discovery work with $2M grant - Stock Titan
- 2026-06-24eXoZymes stock rises on $2M NIH grant for cannabinoid work - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.